iv being debated and established by regulators in the precarious position of balancing the protection of patients with clinical progress and scientific innovation. Practitioners can assuage the concerns of the regulators by self-imposition of more rigorous clinical practices, with self-policing to limit bad actors and encourage good and ethical behavior.
The growth of investigations in the regenerative medicine space has grown upwards of 300% since 1996 17 . The overall community has witnessed unprecedented levels of collaboration at both the academic and community levels. This has come in the form of multi-centric trials and the creation of network, community based clinical registries. With this, remains great opportunities for the strong growth of evidence-based research and peerto-peer learning coupled with joint advocacy activity. The strength in numbers and shared common interest allows for the opportunity for powerful advocates. Additionally, as consensus among stakeholders is established, the collective strength available will effectively shape the regulatory conversation and subsequent policy.
The future is present, and innovations abound. New technology is transforming the way that care is delivered to patients. Needle free injection technology (NFIT) is a broad concept that includes a wide range of drug and or cellular delivery systems that administer injectates through the skin by either shockwave, pressure via gas or electrophoresis that eliminate the need for hypodermic needle. These systems are able to administer highly viscous products which cannot be administered by traditional needle and syringe systems, further adding to the usefulness of the technology. Another innovation is the use of nanogold particles to induce increased production of regenerative cytokines and growth factors 7 to treat degenerative spine, joint, and tendon disorders 20 . Despite being a relatively new technique, chimeric antigen receptor T cell (CAR-T) immunotherapy has gained significant ground for treating both blood based and solid tumor malignances in recent years with approved therapies currently available for patients. What is little known is that this type of therapy is being used with traditional chemotherapeutics in the lower income countries to improve clinical outcomes at lower cost 21 . Additionally, it is also at the investigational stage for other auto-immune disorders that affect bone and joints. Capabilities to identify genetic abnormalities that affect bone and joint conditions have really been critical in advancing therapeutics directed specifically at underlying abnormalities. With the advent of iPS (induced pluripotent stem cells) and CRISPR (clustered regularly interspaced short palindromic repeats) the possibility of editing genes has become a reality. SMART cells (Stem cells Modified for Autonomous regenerative therapy) are one such engineered product that can secrete proteins that antagonize catabolic cytokines such as IL-1 and TNF-a that is rapidly responsive and self-regulated 22 . The future is bright, and exciting. Full of possibilities and creations not even conceived yet, coupled with unfettered collaboration, the multiverse is the limit.
